Psyence Group Inc Completes Reverse Takeover Transaction and Completes Non-brokered Financing

    NEXT STORY
    CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
    PREV STORY
    Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Psyence Group Inc Completes Reverse Takeover Transaction and Completes Non-brokered Financing

    NEXT STORY
    CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
    PREV STORY
    Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies 

    MENLO PARK, Calif. and SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., ...

    author_avatar
    NASDAQ Market News

    Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer

    - Mr. Seth to serve as Chief Executive Officer and Chairman of the Board ...

    author_avatar
    NASDAQ Market News

    Sun BioPharma, Inc. Provides a Business Update and Files Report for Q1 2019

    author_avatar
    NASDAQ Market News